

Louis Lacombe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9484502/publications.pdf>

Version: 2024-02-01

118
papers

9,397
citations

87888

38
h-index

39675

94
g-index

119
all docs

119
docs citations

119
times ranked

12048
citing authors

#	ARTICLE	IF	CITATIONS
1	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , 2015, 163, 1011-1025.	28.9	2,435
2	A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1458-1468.	6.3	1,557
3	Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2004, 96, 879-882.	6.3	1,081
4	Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature</i> , 2017, 541, 359-364.	27.8	462
5	An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. <i>Lancet, The</i> , 2008, 372, 145-154.	13.7	312
6	Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. <i>BJU International</i> , 2011, 108, 539-545.	2.5	156
7	CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy. <i>Cancer Research</i> , 2015, 75, 950-962.	0.9	150
8	Male urethral carcinoma: analysis of treatment outcome. <i>Urology</i> , 1999, 53, 1126-1132.	1.0	148
9	A Prostate Cancer "Nimboſus" Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017, 72, 665-674.	1.9	142
10	Deletions of the INK4A Gene in Superficial Bladder Tumors. <i>American Journal of Pathology</i> , 1999, 155, 105-113.	3.8	121
11	Evaluation of fluorodeoxyglucose positron emission tomography with computed tomography for staging of urothelial carcinoma. <i>BJU International</i> , 2010, 106, 658-663.	2.5	111
12	Bladder Tumor Infiltrating Mature Dendritic Cells and Macrophages as Predictors of Response to Bacillus Calmette-Guérin Immunotherapy. <i>European Urology</i> , 2009, 55, 1386-1396.	1.9	97
13	The Impact of Solitary and Multiple Positive Surgical Margins on Hard Clinical End Points in 1712 Adjuvant Treatment-ŒNaive pT2Œ4 NO Radical Prostatectomy Patients. <i>European Urology</i> , 2013, 64, 19-25.	1.9	82
14	Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. <i>European Urology</i> , 2015, 67, 803-812.	1.9	78
15	High frequency of MAGEŒ4 and MAGEŒ9 expression in highŒrisk bladder cancer. <i>International Journal of Cancer</i> , 2009, 125, 1365-1371.	5.1	77
16	Progression From High-Grade Prostatic Intraepithelial Neoplasia to Cancer: A Randomized Trial of Combination Vitamin-E, Soy, and Selenium. <i>Journal of Clinical Oncology</i> , 2011, 29, 2386-2390.	1.6	70
17	Psychological Functioning Associated with Prostate Cancer: Cross-Sectional Comparison of Patients Treated with Radiotherapy, Brachytherapy, or Surgery. <i>Journal of Pain and Symptom Management</i> , 2005, 30, 474-484.	1.2	67
18	CUA guidelines on the management of non-muscle invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2015, 9, 690.	0.6	67

#	ARTICLE	IF	CITATIONS
19	Carcinoma of the upper urinary tract. <i>Cancer</i> , 2009, 115, 2853-2862.	4.1	62
20	Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes. <i>Urology</i> , 2016, 94, 154-160.	1.0	60
21	NEOADJUVANT HORMONAL THERAPY BEFORE RADICAL PROSTATECTOMY AND RISK OF PROSTATE SPECIFIC ANTIGEN FAILURE. <i>Journal of Urology</i> , 1999, 162, 2024-2028.	0.4	58
22	Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 881-892.	3.4	57
23	Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. <i>Canadian Urological Association Journal</i> , 2013, 1, 377.	0.6	55
24	Deletions of the Androgen-Metabolizing <i>UGT2B</i> Genes Have an Effect on Circulating Steroid Levels and Biochemical Recurrence after Radical Prostatectomy in Localized Prostate Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1550-E1557.	3.6	54
25	Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression. <i>Clinical Cancer Research</i> , 2013, 19, 699-709.	7.0	54
26	The Contemporary Role of Lymph Node Dissection During Nephroureterectomy in the Management of Upper Urinary Tract Urothelial Carcinoma: The Canadian Experience. <i>Urology</i> , 2012, 79, 840-845.	1.0	53
27	Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. <i>BJU International</i> , 2012, 110, 1317-1323.	2.5	50
28	Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. <i>BJU International</i> , 2013, 112, 791-797.	2.5	49
29	Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: Assessment of adequate renal function and influence on outcome. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 31.e17-31.e24.	1.6	49
30	Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2013, 3, 73.	0.6	48
31	FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. <i>Cancer Imaging</i> , 2015, 15, 2.	2.8	47
32	Genome-wide germline correlates of the epigenetic landscape of prostate cancer. <i>Nature Medicine</i> , 2019, 25, 1615-1626.	30.7	45
33	Canadian guidelines for the management of the small renal mass (SRM). <i>Canadian Urological Association Journal</i> , 2015, 9, 160.	0.6	45
34	Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: Results from the Canadian Upper Tract Collaboration1Co-first authors.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 839-845.	1.6	44
35	Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer. <i>International Journal of Cancer</i> , 2008, 122, 1592-1597.	5.1	43
36	Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy. <i>Canadian Urological Association Journal</i> , 2010, 4, 168-173.	0.6	43

#	ARTICLE	IF	CITATIONS
37	SRD5A Polymorphisms and Biochemical Failure After Radical Prostatectomy. <i>European Urology</i> , 2011, 60, 1226-1234.	1.9	41
38	Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer. <i>International Journal of Cancer</i> , 2014, 135, 2661-2667.	5.1	40
39	The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 486.e1-486.e7.	1.6	37
40	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , 2017, 72, 22-31.	1.9	37
41	Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1161-1165.	1.6	36
42	The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression. <i>European Urology</i> , 2016, 69, 601-609.	1.9	36
43	Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer. <i>Cancer</i> , 2008, 113, 710-716.	4.1	35
44	Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer. , 1996, 69, 110-113.		34
45	Salvage Therapy With Bicalutamide 150 mg in Nonmetastatic Castration-resistant Prostate Cancer. <i>Urology</i> , 2010, 76, 1189-1193.	1.0	34
46	Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. <i>International Journal of Cancer</i> , 2001, 95, 135-139.	5.1	33
47	The Impact of Germline Genetic Variations in Hydroxysteroid (17-Beta) Dehydrogenases on Prostate Cancer Outcomes After Prostatectomy. <i>European Urology</i> , 2012, 62, 88-96.	1.9	33
48	Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative. <i>Canadian Urological Association Journal</i> , 2017, 11, 182.	0.6	33
49	The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence. <i>Canadian Urological Association Journal</i> , 2014, 8, 845.	0.6	32
50	Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors. , 1998, 75, 819-824.		31
51	Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy. <i>Prostate</i> , 2004, 58, 269-276.	2.3	30
52	Quality indicators in the management of bladder cancer: A modified Delphi study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 328-334.	1.6	29
53	Steroidogenic Germline Polymorphism Predictors of Prostate Cancer Progression in the Estradiol Pathway. <i>Clinical Cancer Research</i> , 2014, 20, 2971-2983.	7.0	27
54	Importance of 5 α -Reductase Gene Polymorphisms on Circulating and Intraprostatic Androgens in Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 576-584.	7.0	27

#	ARTICLE	IF	CITATIONS
55	Insulin-Like Growth Factor Binding Protein 2: An Androgen-Dependent Predictor of Prostate Cancer Survival. <i>European Urology</i> , 2005, 47, 695-702.	1.9	26
56	Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: Results from a Canadian multicenter collaboration. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 441-448.	1.6	26
57	Age ≥ 80 years is independently associated with survival outcomes after radical cystectomy: Results from the Canadian Bladder Cancer Network Database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 825-832.	1.6	25
58	Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 486.e17-486.e23.	1.6	25
59	Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration. <i>European Urology Focus</i> , 2019, 5, 998-1006.	3.1	25
60	Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy. <i>Diagnostic Pathology</i> , 2015, 10, 67.	2.0	23
61	Validation of the prognostic value of NF- κ B p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network. <i>PLoS Medicine</i> , 2019, 16, e1002847.	8.4	23
62	Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes?. <i>World Journal of Urology</i> , 2012, 30, 761-767.	2.2	22
63	Renal cell carcinoma with thrombus extending to the hepatic veins or right atrium: operative strategies based on 41 consecutive patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, 317-321.	1.4	21
64	Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 300.e9-300.e15.	1.6	21
65	Strategies for Biochemical and Pathologic Quality Assurance in a Large Multi-Institutional Biorepository; The Experience of the PROCURE Quebec Prostate Cancer Biobank. <i>Biopreservation and Biobanking</i> , 2013, 11, 285-290.	1.0	17
66	Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience. <i>Canadian Urological Association Journal</i> , 2011, 5, 83-87.	0.6	16
67	Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 363.e7-363.e11.	1.6	16
68	Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer. <i>BJU International</i> , 2019, 123, 624-631.	2.5	16
69	Can biological markers predict recurrence and progression of superficial bladder cancer?. <i>Current Opinion in Urology</i> , 2000, 10, 441-445.	1.8	15
70	Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy. <i>European Urology Focus</i> , 2017, 3, 639-642.	3.1	15
71	Banking of fresh-frozen prostate tissue using the alternate mirror image protocol: methods, validation, and impact on the pathological prognostic parameters in radical prostatectomy. <i>Cell and Tissue Banking</i> , 2012, 13, 631-638.	1.1	14
72	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. <i>BMC Urology</i> , 2018, 18, 78.	1.4	14

#	ARTICLE	IF	CITATIONS
73	Substratification of high-risk localised prostate cancer treated by radical prostatectomy. World Journal of Urology, 2008, 26, 225-229.	2.2	13
74	Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer. World Journal of Urology, 2014, 32, 1295-1301.	2.2	13
75	A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 701-706.	2.5	13
76	Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression. British Journal of Cancer, 2020, 122, 1068-1076.	6.4	13
77	Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Nonâ€Muscle-Invasive Bladder Cancer: A Geneâ€Smoking Interaction. Cancer Prevention Research, 2016, 9, 189-195.	1.5	11
78	A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine. Canadian Urological Association Journal, 2020, 14, 319-321.	0.6	11
79	Prostatic intraepithelial neoplasia in TURP specimens and subsequent prostate cancer. Canadian Journal of Urology, 2006, 13, 3255-60.	0.0	11
80	Low level of the X-linked ribosomal protein S4 in human urothelial carcinomas is associated with a poor prognosis. Biomarkers in Medicine, 2015, 9, 187-197.	1.4	10
81	Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study. Nutrition and Cancer, 2017, 69, 1196-1204.	2.0	10
82	Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with lowâ€risk prostate cancer receiving 5Î±â€reductase inhibitors. BJU International, 2018, 121, 399-404.	2.5	10
83	Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma. Canadian Urological Association Journal, 2018, 12, 243-251.	0.6	10
84	Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation. Drug Metabolism and Disposition, 2020, 48, 75-84.	3.3	10
85	The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy. Endocrine-Related Cancer, 2015, 22, 77-85.	3.1	9
86	Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?. Clinical Genitourinary Cancer, 2019, 17, e1122-e1128.	1.9	9
87	Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival. World Journal of Urology, 2021, 39, 1549-1558.	2.2	9
88	Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort. Canadian Urological Association Journal, 2012, 6, E217-23.	0.6	9
89	Improved cancer specificâ€survival in patients with carcinoma invading bladder muscle expressing cycloâ€oxygenaseâ€2. BJU International, 2011, 108, 531-537.	2.5	8
90	Surgical Management of Stage T1 Renal Tumors in Canadian Academic Centers. Canadian Urological Association Journal, 2015, 9, 99.	0.6	8

#	ARTICLE	IF	CITATIONS
91	Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody. Drug Metabolism and Disposition, 2019, 47, 444-452.	3.3	8
92	Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer – Abridged version. Canadian Urological Association Journal, 2021, 15, 230-9.	0.6	8
93	Extragenital Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy. Journal of Urology, 2020, 203, 940-948.	0.4	8
94	The relationship between body-mass index, physical activity, and pathologic and clinical outcomes after radical prostatectomy for prostate cancer. World Journal of Urology, 2019, 37, 789-798.	2.2	7
95	Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer. Canadian Urological Association Journal, 2021, 15, E424-E460.	0.6	7
96	Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada. Canadian Urological Association Journal, 2012, 6, 455-62.	0.6	7
97	Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal health care system. Canadian Urological Association Journal, 2013, 7, 667.	0.6	6
98	Discordance between testosterone measurement methods in castrated prostate cancer patients. Endocrine Connections, 2019, 8, 132-140.	1.9	6
99	Early detection of prostate cancer local recurrence by urinary prostate-specific antigen. Canadian Urological Association Journal, 2013, 3, 213.	0.6	5
100	A Simple Variable Number of Tandem Repeat-Based Genotyping Strategy for the Detection of Handling Errors and Validation of Sample Identity in Biobanks. Biopreservation and Biobanking, 2016, 14, 383-389.	1.0	5
101	Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review. Canadian Urological Association Journal, 2017, 11, 419-24.	0.6	5
102	Best practices for enhancing surgical research: a perspective from the Canadian Association of Chairs of Surgical Research. Canadian Journal of Surgery, 2019, 62, 488-498.	1.2	5
103	18F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy. Canadian Urological Association Journal, 2021, 15, 301-307.	0.6	5
104	Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression. British Journal of Cancer, 2021, 125, 78-84.	6.4	5
105	A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores. Pathology and Oncology Research, 2019, 25, 979-986.	1.9	4
106	Achieving the “trifecta” with open versus minimally invasive partial nephrectomy. World Journal of Urology, 2021, 39, 1569-1575.	2.2	4
107	Cystatin C for early detection of acute kidney injury after laparoscopic partial nephrectomy. Urology Annals, 2014, 6, 298.	0.6	3
108	Blood management and radical retropubic prostatectomy: Quebec experience. Canadian Journal of Urology, 1999, 6, 727-731.	0.0	3

#	ARTICLE	IF	CITATIONS
109	Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder Cancer Network experience. Canadian Urological Association Journal, 2012, 6, E116-E120.	0.6	2
110	Comorbidity Status Does Not Independently Predict Survival Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. European Urology, 2013, 64, 518-519.	1.9	2
111	Complete Penile Necrosis in a Patient With Heparin-induced Thrombocytopenia: A Case Report. Urology Case Reports, 2014, 2, 21-23.	0.3	2
112	Psychosocial adjustment to a prostate cancer diagnosis in a cohort of radical prostatectomy patients in Quebec, Canada. Psycho-Oncology, 2019, 28, 839-846.	2.3	2
113	Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer. Asian Journal of Andrology, 2022, 24, 21.	1.6	2
114	Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy. Clinical Nutrition ESPEN, 2022, 47, 221-226.	1.2	2
115	Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy. World Journal of Urology, 2013, 31, 293-297.	2.2	1
116	633: A Multicenter, Randomized, Phase 3 Trial of a Novel Autologous Therapeutic Vaccine (VITESPEN) VS. Observation as Adjuvant Therapy in Patients at High Risk of Recurrence after Nephrectomy for Renal Cell Carcinoma. Journal of Urology, 2007, 177, 212-212.	0.4	1
117	Double inferior vena cava systems during retroperitoneal surgery: Description of a systematic approach to a rare and challenging anatomic variant. Journal of Vascular Surgery Cases and Innovative Techniques, 2022, 8, 81-84.	0.6	0
118	Sex steroid modulation of macrophages within the prostate tumor microenvironment.. American Journal of Clinical and Experimental Urology, 2022, 10, 98-110.	0.4	0